Related Experiment Video
Updated: Dec 23, 2025
11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
39.0K
The Noradrenergic System in Parkinson's Disease
Elena Paredes-Rodriguez1,2, Sergio Vegas-Suarez1,2, Teresa Morera-Herreras1,2
1Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.
Frontiers in Pharmacology
|April 24, 2020
Summary
Parkinson's disease (PD) involves early degeneration of the locus coeruleus (LC), impacting non-motor symptoms and drug efficacy. Understanding the noradrenergic system is crucial for effective PD treatment strategies.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) neurodegeneration is a progressive, multi-stage process.
- Damage to areas like the locus coeruleus (LC) precedes substantia nigra pars compacta neuronal loss.
- The LC, a key noradrenergic nucleus, influences motor, sensory, autonomic functions, and emotional memory.
Purpose of the Study:
- To review the functional status of the noradrenergic system in PD.
- To examine the LC's role in PD pathogenesis and non-motor symptoms.
- To assess the impact of noradrenergic system dysfunction on pharmacological treatments for PD.
Main Methods:
- Review of preclinical and clinical publications.
- Analysis of the noradrenergic system's role in PD progression.
- Focus on the interplay between noradrenergic dysfunction and L-DOPA therapy.
Main Results:
- Early degeneration of the LC is a hallmark of PD.
- LC neuron modifications affect treatment efficacy and non-motor symptoms.
- Noradrenergic system dysfunction can influence PD progression and drug interactions.
Conclusions:
- The noradrenergic system, particularly the LC, plays a critical role in early PD.
- Understanding LC function is vital for managing non-motor symptoms in PD.
- Noradrenergic system status impacts the effectiveness of PD pharmacotherapies, including L-DOPA.
Related Concept Videos
01:24Parkinson's Disease: Treatment
856
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
856
01:15Parkinson's Disease: Overview
1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
01:37Neural Regulation
42.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K
01:29Drugs Affecting Neurotransmitter Synthesis
2.0K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.4K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.4K
01:27Adrenergic Neurons: Neurotransmission
5.0K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.0K